6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial

JAMA

Volumn 292, Issue 7, 2004, Pages 821-827

  D'Amico, Anthony V ^a   Manola, Judith ^a   Loffredo, Marian ^a   Renshaw, Andrew A ^a   DellaCroce, Alyssa ^a   Kantoff, Philip W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; FLUTAMIDE; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ANDROGEN SUPPRESSION THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RADIATION DOSE; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SCORING SYSTEM; SURVIVAL RATE; THREE DIMENSIONAL CONFORMAL RADIATION THERAPY; ADENOCARCINOMA; BLOOD; COMPARATIVE STUDY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; SURVIVAL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; FLUTAMIDE; GOSERELIN; HUMANS; LEUPROLIDE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; SURVIVAL ANALYSIS;

EID: 4043153049     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.7.821     Document Type: Article

References (21)

1. D'Amico AV, Moul J, Carroll P, et al. Cancer specific mortality following surgery or radiation for patients with clinically localized prostate cancer managed during the PSA era. J Clin Oncol. 2003;21:2163-2172.
2. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 2002;360:103-106.
3. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097-1105.
4. D'Amico AV, Moul J, Carroll P, et al. Surrogate marker for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376-1383.
5. Bolla M, Gonsalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295-300.
6. Holzbeierlein JM, Castle E, Thrasher JB. Complications of androgen deprivation therapy: prevention and treatment. Oncology. 2004;18:303-309.
7. Beahrs OH, Henson DE, Hutter RVP. American Joint Committee on Cancer: Manual for Staging Cancer. 4th ed. Philadelphia, Pa: JP Lippincott; 1992.
8. Gleason DF, and the Veterans Administration Cooperative Urological Research Group. Histologic grading and staging of prostatic carcinoma. In: Tannenbaum M, ed. Urologic Pathology. Philadelphia, Pa: Lea & Febiger; 1977:171-187.
9. Relative Effectiveness and Cost-Effectiveness of Methods of Androgen Suppression in the Treatment of Advanced Prostatic Cancer. Rockville, Md: Agency for Health Care Policy and Research; 1999. Available at: http://www.ahrq.gov/ clinic/epcsums/prossumm.htm. Accessibility verified July 14, 2004.
10. Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0: an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47:13-47.
11. Mehta CR, Patel NR, Tsiatis AA. Exact significance testing for ordered categorical data. Biometrics. 1984;40:819-825.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
13. Gaynor JJ, Feur EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993;88:400-409.
14. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc Ser A. 1972;135:185-206.
15. Klein JP, Moeschberger ML, eds. Survival Analysis. New York, NY: Springer-Verlag; 1997:96-100, 229-268.
16. Smith MR. Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. Cancer Metastasis Rev. 2002;21:159-166.
17. Green HJ, Pakenham KI, Headley BC, et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int. 2002;90:427-432.
18. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-1022.
19. Chen Z, Maricic M, Nguyen P, et al. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer. 2002;95:2136-2144.
20. Roach M 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression. J Clin Oncol. 2003;21:1904-1911.
21. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. J Clin Oncol. 2003;21:3972-3978.